Differences in Structural Proteins in Prostate Cells May GiveEarly Indications of Cancer

Publication
Article
OncologyONCOLOGY Vol 9 No 8
Volume 9
Issue 8

Variations in structural proteins found in the nucleus of prostatecells may indicate whether a cell will become cancerous, according

Variations in structural proteins found in the nucleus of prostatecells may indicate whether a cell will become cancerous, accordingto a Pittsburgh Cancer Institute (PCI) investigator.

Robert Getzenberg, PhD, Assistant Professor of Pathology, Surgery,Medicine and Pharmacology at PCI, presented his findings at theannual meeting of the American Urological Association in Las Vegas.Dr. Getzenberg's research focuses on nuclear alterations thatare prevalent in prostate cancer cells and are commonly used asa pathological marker for cancer.

Researchers looked at structural proteins within the cell's nucleus.These proteins form the "scaffolding framework" of thenucleus, and are involved in DNA organization. "When we startedlooking at the nuclear matrix proteins in the cells of prostatetissue, we found that there is a difference between normal andcancer cells," Dr. Getzenberg said.

Variations in nuclear matrix proteins may be a useful tool fordiagnosing early stages of prostate cancer, and may offer newstrategies for treatment, according to the investigators.

Dr. Getzenberg and his colleagues identified proteins that werepresent only in the normal prostate and were missing in both prostatecancer and benign prostatic hyperplasia (BPH); proteins foundonly in the prostate cancer cells and missing in the normal prostateand BPH; and proteins that appeared in both normal and BPH samplesbut were absent from prostate cancers.

"Differences in nuclear matrix proteins may be a fundamentalcause of, or a major contributor to, the pattern of altered geneexpression identified in prostate cancer," Dr. Getzenbergsaid.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content